BCG无应答非肌层浸润性膀胱癌不同治疗模式的成本-效果分析
本研究从支付方视角构建Markov模型,比较BCG无应答NMIBC中根治性膀胱切除术(RC)、吉西他滨/多西他赛、帕博利珠单抗和热灌注膀胱内化疗(HIVEC)的成本-效果;蒙特卡洛模拟显示,在支付意愿阈值<€50 000/QALY时HIVEC为优选方案,帕博利珠单抗需降价至少70%才具成本效果。
要点
- 10年 horizon 下,与RC相比吉西他滨/多西他赛、HIVEC和帕博利珠单抗的ICER分别为€26 482、€42 567和€184 533/QALY。
- 蒙特卡洛模拟显示,在支付意愿<€50 000/QALY假设下HIVEC为治疗选择。
- 帕博利珠单抗按当前价格仅当降价至少70%时才具成本效果。
核心结论
- 考虑支付意愿<€50 000/QALY时,吉西他滨/多西他赛和HIVEC在BCG难治性NMIBC中是非常具有成本效果的治疗选择,而RC仍是最便宜的选项。
- 按当前价格,帕博利珠单抗仅当降价至少70%时才具成本效果。
研究设计与样本
- 从支付方视角构建Markov模型,临床数据来源于单臂试验(膀胱内吉西他滨/多西他赛和帕博利珠单抗)以及本中心(科隆泌尿肿瘤中心)接受HIVEC作为膀胱内挽救化疗的患者(n=29)。
- 成本采用非商业诊断相关分组(DRG)分组器模拟,效用值取自可比的成本-效果研究。
- 采用蒙特卡洛模拟识别最优治疗,在支付意愿阈值€50 000/QALY下比较增量成本效果比(ICER)。
主要发现
- 10年 horizon 下,吉西他滨/多西他赛、HIVEC和帕博利珠单抗的成本分别为€48 353、€64 438和€204 580,QALY增益分别为6.16、6.48和6.00。
- 与RC(总成本€21 871,QALY增益5.01)相比,吉西他滨/多西他赛、HIVEC和帕博利珠单抗的ICER分别为€26 482、€42 567和€184 533。
- 蒙特卡洛模拟显示,在支付意愿<€50 000/QALY假设下,HIVEC为治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Radical cystectomy (RC) is the standard of care (SOC) in BCG-unresponsive NMIBC and is associated with a significant health-related quality-of-life burden. Recently, promising results have been published on Gemcitabine/Docetaxel, Pembrolizumab, and Hyperthermic Intravesical Chemotherapy (HIVEC) as salvage therapy options trying to increase the rate of bladder preservation. Here, we performed a Cost-Effectiveness-Analysis of those treatment modalities. PATIENTS AND METHODS: We developed a Markov model from a payer's perspective drawing on clinical data of single-arm trials testing intravesical gemcitabine/docetaxel and pembrolizumab in BCG-unresponsive NMIBC, as well as clinical data from patients receiving hyperthermic intravesical chemotherapy HIVEC (n = 29) as intravesical salvage chemotherapy at our uro-oncological centre in Cologne. Costs were simulated utilising a non-commercial diagnosis-related groups grouper, utilities were derived from comparable cost-effectiveness studies. We used a Monte Carlo simulation to identify the optimal treatment, comparing the incremental cost effectiveness ratios (ICERs) at a willingness-to-pay threshold of €50 000 (euro)/quality-adjusted life year (QALY). RESULTS: Over a horizon of 10 years, gemcitabine/docetaxel, HIVEC, and pembrolizumab were associated with costs of €48 353, €64 438, and €204 580, as well as a gain of QALYs of 6.16, 6.48, and 6.00, resulting in an ICER of €26 482, €42 567, and €184 533 respectively, in comparison to RC with total costs of €21 871 and a gain of QALYs of 5.01. Monte Carlo simulation identified HIVEC as the treatment of choice under assumption of a WTP of <€50 000. CONCLUSION: Considering a WTP of <€50 000/QALY, gemcitabine/docetaxel and HIVEC are highly cost-effective therapeutic options in BCG-refractory NMIBC, while RC remains the cheapest option. At its current price, pembrolizumab would only be cost-effective assuming a price reduction of at least 70%.
引用
- Rieger C, Schlüchtermann J, Storz E, et al. Cost-effectiveness analysis of different treatment modalities in BCG-unresponsive NMIBC. BJU Int. 2024. PMID: 38491799. doi:10.1111/bju.16332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。